Seneca Therapeutics
Focus: Seneca Therapeutics is an early-stage biotechnology company focused on oncolytic immunotherapy, leveraging viral-based approaches to treat cancer. Founded in 2023 and headquartered in Blue Bell, PA, the company is currently at Series B funding stage with no commercial products yet.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Funding Stage
SERIES B
Open Jobs
0
About Seneca Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Seneca Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Seneca Valley Virus-001
Neuroendocrine CarcinomaClinical Trials (1)
NCT06889493SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
Phase 1Help build intelligence for Seneca Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.